Study Design and Ethical Considerations
The present study is a prospective randomized controlled clinical trial investigating the
efficacy of a commercially available mouthwash containing 0.05% CPC and 0.05% CHX
(PerioAid Active Control; Dentaid SL) as compared to a placebo mouthwash (0.9% NaCl) on
reducing the intraoral viral load and infectivity in SARS-CoV-2–positive patients.The study design followed the requirements outlined in the Consolidated Standards of
Reporting Trials (CONSORT) 2010 statement and was approved by the internal review board of
the University of Regensburg (ref. 20-1787_3-101) in accordance with the 1964 Declaration
of Helsinki and its later amendments or comparable ethical standards. The study has been
prospectively registered at the German Clinical Trials Register (ref. DRKS00027812).